Thu. 16 May 2024, 6:49am ET
Benzinga
Biotech, Large Cap, News, Health Care, General
- Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes
- Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists